Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, both based in Boston, will transition to a new care model for breast cancer services, effective Oct. 19.
Outpatient breast oncology services will be provided at Dana-Farber, while breast cancer surgical services will be provided by surgeons at Beth Israel Deaconess Medical Center, according to an Oct. 15 news release from Dana-Farber.
The breast cancer surgical team will be led by Elizabeth Mittendorf, MD, PhD, chief of the division of breast surgery at Beth Israel Deaconess Medical Center; chief of multidisciplinary oncology at Dana-Farber; and co-leader of the Breast Program for the Boston-based Harvard Cancer Consortium.
Other cancer treatment areas will transition to new care models through a phased approach over the next several years as part of Dana-Farber and Beth Israel Deaconess Medical Center’s cancer care partnership.
The cancer care collaboration includes a $1.68 billion cancer hospital currently under construction. The 300-bed facility will be owned and operated by Dana-Farber and clinically supported in collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
